Home › NDC Lookup › RxCUI directory › RxCUI 2623654

Olutasidenib 150 MG Oral Capsule [Rezlidhia] — RxCUI 2623654

RxNorm drug concept · Semantic branded drug
RxCUI 2623654 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2623654
Official nameOlutasidenib 150 MG Oral Capsule [Rezlidhia]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRezlidhia 150 MG Oral Capsule
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Olutasidenib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Rezlidhia is prescribed for a specific type of blood cancer called acute myeloid leukemia (AML) that has either come back after treatment or stopped responding to it. But it only w...
  • What exactly is this medication for — why did my doctor prescribe it?
  • Yes, it really does matter. Studies showed that taking olutasidenib with a high-fat meal increased the amount of drug absorbed into your blood by a very large amount — which could...
  • Why do I have to take it on an empty stomach? Does it really matter?
📖 Read our full Olutasidenib guide →

🕸️ Concept Web — How Olutasidenib 150 MG Oral Capsule [Rezlidhia] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Olutasidenib 150 MG Oral Capsule [Rezlidhia] RxCUI 2623654

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Olutasidenib 2623641
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Rezlidhia 2623649
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Olutasidenib Oral Capsule 2623647
    • Olutasidenib Oral Product 2623645
    • Olutasidenib Pill 2623646
    • Olutasidenib Oral Capsule [Rezlidhia] 2623653
    • Rezlidhia Oral Product 2623651
    • Rezlidhia Pill 2623652
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Olutasidenib 150 MG Oral Capsule SCD · 2623648
  • Olutasidenib 150 MG SCDC · 2623644
  • Olutasidenib Oral Capsule SCDF · 2623647
  • Olutasidenib Oral Product SCDG · 2623645
  • Olutasidenib Pill SCDG · 2623646

Brand-Name Concepts

  • Olutasidenib 150 MG [Rezlidhia] SBDC · 2623650
  • Olutasidenib Oral Capsule [Rezlidhia] SBDF · 2623653
  • Rezlidhia Oral Product SBDG · 2623651
  • Rezlidhia Pill SBDG · 2623652
  • Rezlidhia BN · 2623649

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2623654 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71332-0005-01 30 CAPSULE in 1 BOTTLE (71332-005-01) REZLIDHIA Rigel Pharmaceuticals, Inc. 2022-12-01
Observed labelers: Rigel Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.